Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study

Circulating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single‐cell molecular analysis is required. We developed the ChimeraX(®)‐i120 platform to facilitate negative enrichment, immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Peng‐Xiang, Sun, Yun‐Fan, Jin, Wei‐Xiang, Cheng, Jian‐Wen, Peng, Hai‐Xiang, Xu, Yang, Zhou, Kai‐Qian, Chen, Li‐Meng, Huang, Kai, Wu, Sui‐Yi, Hu, Bo, Zhang, Ze‐Fan, Guo, Wei, Cao, Ya, Zhou, Jian, Fan, Jia, Yang, Xin‐Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410565/
https://www.ncbi.nlm.nih.gov/pubmed/33301640
http://dx.doi.org/10.1002/1878-0261.12876
_version_ 1783747139428417536
author Wang, Peng‐Xiang
Sun, Yun‐Fan
Jin, Wei‐Xiang
Cheng, Jian‐Wen
Peng, Hai‐Xiang
Xu, Yang
Zhou, Kai‐Qian
Chen, Li‐Meng
Huang, Kai
Wu, Sui‐Yi
Hu, Bo
Zhang, Ze‐Fan
Guo, Wei
Cao, Ya
Zhou, Jian
Fan, Jia
Yang, Xin‐Rong
author_facet Wang, Peng‐Xiang
Sun, Yun‐Fan
Jin, Wei‐Xiang
Cheng, Jian‐Wen
Peng, Hai‐Xiang
Xu, Yang
Zhou, Kai‐Qian
Chen, Li‐Meng
Huang, Kai
Wu, Sui‐Yi
Hu, Bo
Zhang, Ze‐Fan
Guo, Wei
Cao, Ya
Zhou, Jian
Fan, Jia
Yang, Xin‐Rong
author_sort Wang, Peng‐Xiang
collection PubMed
description Circulating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single‐cell molecular analysis is required. We developed the ChimeraX(®)‐i120 platform to facilitate negative enrichment, immunofluorescent labeling, and machine learning‐based identification of CTCs. Analytical performances were evaluated, and a total of 477 participants were enrolled to validate the clinical feasibility of ChimeraX(®)‐i120 CTC detection. We analyzed copy number alteration profiles of isolated single cells. The ChimeraX(®)‐i120 platform had high sensitivity, accuracy, and reproducibility for CTC detection. In clinical samples, an average value of > 60% CTC‐positive rate was found for five cancer types (i.e., liver, biliary duct, breast, colorectal, and lung), while CTCs were rarely identified in blood from healthy donors. In hepatocellular carcinoma patients treated with curative resection, CTC status was significantly associated with tumor characteristics, prognosis, and treatment response (all P < 0.05). Single‐cell sequencing analysis revealed that heterogeneous genomic alteration patterns resided in different cells, patients, and cancers. Our results suggest that the use of this ChimeraX(®)‐i120 platform and the integrated workflow has validity as a tool for CTC detection and downstream genomic profiling in the clinical setting.
format Online
Article
Text
id pubmed-8410565
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84105652021-09-03 Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study Wang, Peng‐Xiang Sun, Yun‐Fan Jin, Wei‐Xiang Cheng, Jian‐Wen Peng, Hai‐Xiang Xu, Yang Zhou, Kai‐Qian Chen, Li‐Meng Huang, Kai Wu, Sui‐Yi Hu, Bo Zhang, Ze‐Fan Guo, Wei Cao, Ya Zhou, Jian Fan, Jia Yang, Xin‐Rong Mol Oncol Research Articles Circulating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single‐cell molecular analysis is required. We developed the ChimeraX(®)‐i120 platform to facilitate negative enrichment, immunofluorescent labeling, and machine learning‐based identification of CTCs. Analytical performances were evaluated, and a total of 477 participants were enrolled to validate the clinical feasibility of ChimeraX(®)‐i120 CTC detection. We analyzed copy number alteration profiles of isolated single cells. The ChimeraX(®)‐i120 platform had high sensitivity, accuracy, and reproducibility for CTC detection. In clinical samples, an average value of > 60% CTC‐positive rate was found for five cancer types (i.e., liver, biliary duct, breast, colorectal, and lung), while CTCs were rarely identified in blood from healthy donors. In hepatocellular carcinoma patients treated with curative resection, CTC status was significantly associated with tumor characteristics, prognosis, and treatment response (all P < 0.05). Single‐cell sequencing analysis revealed that heterogeneous genomic alteration patterns resided in different cells, patients, and cancers. Our results suggest that the use of this ChimeraX(®)‐i120 platform and the integrated workflow has validity as a tool for CTC detection and downstream genomic profiling in the clinical setting. John Wiley and Sons Inc. 2020-12-25 2021-09 /pmc/articles/PMC8410565/ /pubmed/33301640 http://dx.doi.org/10.1002/1878-0261.12876 Text en © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Wang, Peng‐Xiang
Sun, Yun‐Fan
Jin, Wei‐Xiang
Cheng, Jian‐Wen
Peng, Hai‐Xiang
Xu, Yang
Zhou, Kai‐Qian
Chen, Li‐Meng
Huang, Kai
Wu, Sui‐Yi
Hu, Bo
Zhang, Ze‐Fan
Guo, Wei
Cao, Ya
Zhou, Jian
Fan, Jia
Yang, Xin‐Rong
Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study
title Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study
title_full Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study
title_fullStr Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study
title_full_unstemmed Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study
title_short Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX(®)‐i120 Platform: A prospective study
title_sort circulating tumor cell detection and single‐cell analysis using an integrated workflow based on chimerax(®)‐i120 platform: a prospective study
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410565/
https://www.ncbi.nlm.nih.gov/pubmed/33301640
http://dx.doi.org/10.1002/1878-0261.12876
work_keys_str_mv AT wangpengxiang circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT sunyunfan circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT jinweixiang circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT chengjianwen circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT penghaixiang circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT xuyang circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT zhoukaiqian circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT chenlimeng circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT huangkai circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT wusuiyi circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT hubo circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT zhangzefan circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT guowei circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT caoya circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT zhoujian circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT fanjia circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy
AT yangxinrong circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy